Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study.
<h4>Background</h4>Although levels of iron are known to be increased in the brains of patients with Parkinson disease (PD), epidemiological evidence on a possible effect of iron blood levels on PD risk is inconclusive, with effects reported in opposite directions. Epidemiological studies...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/1a3b43cf16a34250b3226fdeb1524b3d |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:1a3b43cf16a34250b3226fdeb1524b3d |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:1a3b43cf16a34250b3226fdeb1524b3d2021-11-18T05:42:35ZSerum iron levels and the risk of Parkinson disease: a Mendelian randomization study.1549-12771549-167610.1371/journal.pmed.1001462https://doaj.org/article/1a3b43cf16a34250b3226fdeb1524b3d2013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23750121/?tool=EBIhttps://doaj.org/toc/1549-1277https://doaj.org/toc/1549-1676<h4>Background</h4>Although levels of iron are known to be increased in the brains of patients with Parkinson disease (PD), epidemiological evidence on a possible effect of iron blood levels on PD risk is inconclusive, with effects reported in opposite directions. Epidemiological studies suffer from problems of confounding and reverse causation, and mendelian randomization (MR) represents an alternative approach to provide unconfounded estimates of the effects of biomarkers on disease. We performed a MR study where genes known to modify iron levels were used as instruments to estimate the effect of iron on PD risk, based on estimates of the genetic effects on both iron and PD obtained from the largest sample meta-analyzed to date.<h4>Methods and findings</h4>We used as instrumental variables three genetic variants influencing iron levels, HFE rs1800562, HFE rs1799945, and TMPRSS6 rs855791. Estimates of their effect on serum iron were based on a recent genome-wide meta-analysis of 21,567 individuals, while estimates of their effect on PD risk were obtained through meta-analysis of genome-wide and candidate gene studies with 20,809 PD cases and 88,892 controls. Separate MR estimates of the effect of iron on PD were obtained for each variant and pooled by meta-analysis. We investigated heterogeneity across the three estimates as an indication of possible pleiotropy and found no evidence of it. The combined MR estimate showed a statistically significant protective effect of iron, with a relative risk reduction for PD of 3% (95% CI 1%-6%; p = 0.001) per 10 µg/dl increase in serum iron.<h4>Conclusions</h4>Our study suggests that increased iron levels are causally associated with a decreased risk of developing PD. Further studies are needed to understand the pathophysiological mechanism of action of serum iron on PD risk before recommendations can be made.Irene PichlerFabiola Del Greco MMartin GögeleChristina M LillLars BertramChuong B DoNicholas ErikssonTatiana ForoudRichard H MyersPD GWAS ConsortiumMichael NallsMargaux F KellerInternational Parkinson's Disease Genomics ConsortiumWellcome Trust Case Control Consortium 2Beben BenyaminJohn B WhitfieldGenetics of Iron Status ConsortiumPeter P PramstallerAndrew A HicksJohn R ThompsonCosetta MinelliPublic Library of Science (PLoS)articleMedicineRENPLoS Medicine, Vol 10, Iss 6, p e1001462 (2013) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R |
| spellingShingle |
Medicine R Irene Pichler Fabiola Del Greco M Martin Gögele Christina M Lill Lars Bertram Chuong B Do Nicholas Eriksson Tatiana Foroud Richard H Myers PD GWAS Consortium Michael Nalls Margaux F Keller International Parkinson's Disease Genomics Consortium Wellcome Trust Case Control Consortium 2 Beben Benyamin John B Whitfield Genetics of Iron Status Consortium Peter P Pramstaller Andrew A Hicks John R Thompson Cosetta Minelli Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study. |
| description |
<h4>Background</h4>Although levels of iron are known to be increased in the brains of patients with Parkinson disease (PD), epidemiological evidence on a possible effect of iron blood levels on PD risk is inconclusive, with effects reported in opposite directions. Epidemiological studies suffer from problems of confounding and reverse causation, and mendelian randomization (MR) represents an alternative approach to provide unconfounded estimates of the effects of biomarkers on disease. We performed a MR study where genes known to modify iron levels were used as instruments to estimate the effect of iron on PD risk, based on estimates of the genetic effects on both iron and PD obtained from the largest sample meta-analyzed to date.<h4>Methods and findings</h4>We used as instrumental variables three genetic variants influencing iron levels, HFE rs1800562, HFE rs1799945, and TMPRSS6 rs855791. Estimates of their effect on serum iron were based on a recent genome-wide meta-analysis of 21,567 individuals, while estimates of their effect on PD risk were obtained through meta-analysis of genome-wide and candidate gene studies with 20,809 PD cases and 88,892 controls. Separate MR estimates of the effect of iron on PD were obtained for each variant and pooled by meta-analysis. We investigated heterogeneity across the three estimates as an indication of possible pleiotropy and found no evidence of it. The combined MR estimate showed a statistically significant protective effect of iron, with a relative risk reduction for PD of 3% (95% CI 1%-6%; p = 0.001) per 10 µg/dl increase in serum iron.<h4>Conclusions</h4>Our study suggests that increased iron levels are causally associated with a decreased risk of developing PD. Further studies are needed to understand the pathophysiological mechanism of action of serum iron on PD risk before recommendations can be made. |
| format |
article |
| author |
Irene Pichler Fabiola Del Greco M Martin Gögele Christina M Lill Lars Bertram Chuong B Do Nicholas Eriksson Tatiana Foroud Richard H Myers PD GWAS Consortium Michael Nalls Margaux F Keller International Parkinson's Disease Genomics Consortium Wellcome Trust Case Control Consortium 2 Beben Benyamin John B Whitfield Genetics of Iron Status Consortium Peter P Pramstaller Andrew A Hicks John R Thompson Cosetta Minelli |
| author_facet |
Irene Pichler Fabiola Del Greco M Martin Gögele Christina M Lill Lars Bertram Chuong B Do Nicholas Eriksson Tatiana Foroud Richard H Myers PD GWAS Consortium Michael Nalls Margaux F Keller International Parkinson's Disease Genomics Consortium Wellcome Trust Case Control Consortium 2 Beben Benyamin John B Whitfield Genetics of Iron Status Consortium Peter P Pramstaller Andrew A Hicks John R Thompson Cosetta Minelli |
| author_sort |
Irene Pichler |
| title |
Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study. |
| title_short |
Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study. |
| title_full |
Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study. |
| title_fullStr |
Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study. |
| title_full_unstemmed |
Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study. |
| title_sort |
serum iron levels and the risk of parkinson disease: a mendelian randomization study. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2013 |
| url |
https://doaj.org/article/1a3b43cf16a34250b3226fdeb1524b3d |
| work_keys_str_mv |
AT irenepichler serumironlevelsandtheriskofparkinsondiseaseamendelianrandomizationstudy AT fabioladelgrecom serumironlevelsandtheriskofparkinsondiseaseamendelianrandomizationstudy AT martingogele serumironlevelsandtheriskofparkinsondiseaseamendelianrandomizationstudy AT christinamlill serumironlevelsandtheriskofparkinsondiseaseamendelianrandomizationstudy AT larsbertram serumironlevelsandtheriskofparkinsondiseaseamendelianrandomizationstudy AT chuongbdo serumironlevelsandtheriskofparkinsondiseaseamendelianrandomizationstudy AT nicholaseriksson serumironlevelsandtheriskofparkinsondiseaseamendelianrandomizationstudy AT tatianaforoud serumironlevelsandtheriskofparkinsondiseaseamendelianrandomizationstudy AT richardhmyers serumironlevelsandtheriskofparkinsondiseaseamendelianrandomizationstudy AT pdgwasconsortium serumironlevelsandtheriskofparkinsondiseaseamendelianrandomizationstudy AT michaelnalls serumironlevelsandtheriskofparkinsondiseaseamendelianrandomizationstudy AT margauxfkeller serumironlevelsandtheriskofparkinsondiseaseamendelianrandomizationstudy AT internationalparkinsonsdiseasegenomicsconsortium serumironlevelsandtheriskofparkinsondiseaseamendelianrandomizationstudy AT wellcometrustcasecontrolconsortium2 serumironlevelsandtheriskofparkinsondiseaseamendelianrandomizationstudy AT bebenbenyamin serumironlevelsandtheriskofparkinsondiseaseamendelianrandomizationstudy AT johnbwhitfield serumironlevelsandtheriskofparkinsondiseaseamendelianrandomizationstudy AT geneticsofironstatusconsortium serumironlevelsandtheriskofparkinsondiseaseamendelianrandomizationstudy AT peterppramstaller serumironlevelsandtheriskofparkinsondiseaseamendelianrandomizationstudy AT andrewahicks serumironlevelsandtheriskofparkinsondiseaseamendelianrandomizationstudy AT johnrthompson serumironlevelsandtheriskofparkinsondiseaseamendelianrandomizationstudy AT cosettaminelli serumironlevelsandtheriskofparkinsondiseaseamendelianrandomizationstudy |
| _version_ |
1718424771981475840 |